Sunday 18 October 2026
Export BNTC’s income statement to Excel — free account
Benitec Biopharma Limited
BNTC Healthcare Biotechnology
In the quarter to June 2026, EPS fell 11.3%, free cash flow grew 38.9% and total debt fell 46.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
8.11
0.35
−4.14%
Follow BNTC
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(53.01%) | (33.50%) | (29.58%) | (33.21%) | |
| (50.76%) | (32.70%) | (28.43%) | (32.28%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(44.89%) | (23.60%) | (22.72%) | (25.80%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.54) | (0.40) | (0.40) | (0.36) | |
Free Cash Flow |
(22.35) | (18.45) | (19.82) | (16.62) | |
Capital Expenditures |
— | (0.03) | (0.03) | (0.10) | |
| Other line items | |||||
Cash ROIC |
(11.85%) | (4.90%) | (5.38%) | (4.65%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.53 | 0.42 | 0.48 | 0.36 | |
Depreciation/Fixed assets |
0.46 | 0.47 | 0.47 | 0.33 | |
Capex/Depreciation |
0.00 | (0.54) | (0.58) | (1.81) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.54) | (0.40) | (0.40) | (0.35) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Oct 2026